The Global Health European and Developing Countries Clinical Trials Partnership 3 Joint Undertaking (GH EDCTP3 JU) has released its Work Programme for 2024.
In 2024, the GH EDCTP3 JU will distribute €140 million through two calls, which are planned to be launched on 18 January 2024, with a stage 1 deadline of 4 April 2024:
The HORIZON-JU-GH-EDCTP3-2024-01-two-stage call covers six topics for Research and Innovation Actions (RIA):
- Developing novel, innovative HIV therapeutics for reducing the disease burden of HIV in sub-Saharan Africa
- Research on existing Malaria vaccines and development of new promising candidates
- Accelerating development and integration of therapeutics against Neglected Tropical Diseases (NTDs) in sub-Saharan Africa
- Tackling Antimicrobial Resistance (AMR) through R&D in novel and existing antimicrobials
- New tools, technologies and approaches for vector control in sub-Saharan Africa
- Innovative digital health solutions for sub-Saharan Africa
The HORIZON-JU-GH-EDCTP3-2024-02-two-stage call will include one topic for Coordination and Support Actions (CSA):
- Global Health EDCTP3 JU training fellowship with a return phase.
The full description of the topics will be available when the calls open.
An information session will take place in early 2024 to provide applicants with further details on the calls for proposals and answer any relevant questions.